NRXS Neuraxis, INC
Electromedical & Electrotherapeutic Apparatus · NYSE · SEC CIK 1933567 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY94.3%
TTM net income YoY-60.5%
TTM EPS YoY-9.1%
Revenue 3-yr CAGR37.0%
Net income 3-yr CAGR—
Margins
Gross margin86.2%
Operating margin-186.2%
Net margin-185.2%
FCF margin—
EBITDA margin-185.0%
Returns
ROE-409.7%
ROA-194.7%
ROIC (approx.)—
Asset turnover1.05x
Leverage & solvency
Liabilities / assets45.6%
Debt / equity0.00x
Current ratio2.10x
Interest coverage-128.36x
Cash quality & payout
Operating cash flow / net income0.53x
Accruals ratio-90.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.03M | $1.93M | $1.61M | $968,127 | $811,414 | $894,086 | $895,655 | $761,165 |
| Cost of revenue | $271,663 | $272,573 | $218,366 | $141,651 | $135,487 | $146,643 | $139,475 | $105,053 |
| Gross profit | $1.76M | $1.66M | $1.39M | $826,476 | $675,927 | $747,443 | $756,180 | $656,112 |
| R&D expense | $288,745 | $274,344 | $99,567 | $146,178 | $130,850 | $115,197 | $117,867 | $138,426 |
| SG&A expense | $7.05M | $2.65M | $2.21M | $1.81M | $1.88M | $1.82M | $2.43M | $1.53M |
| Operating income | -$6.58M | -$2.12M | -$1.74M | -$1.72M | -$2.10M | -$1.72M | -$2.30M | -$1.47M |
| Interest expense | $20,126 | $19,794 | $26,189 | $28,636 | $29,661 | $13,434 | $2,237 | $2,394 |
| Net income | -$6.55M | -$2.09M | -$1.76M | -$1.71M | -$2.12M | -$1.69M | -$2.28M | -$1.45M |
| EBITDA | -$6.56M | -$2.11M | -$1.72M | -$1.69M | -$2.08M | -$1.70M | -$2.29M | -$1.46M |
| EPS (basic) | -0.52 | -0.19 | -0.18 | — | -0.24 | -0.22 | -0.33 | — |
| EPS (diluted) | -0.52 | -0.19 | -0.18 | — | -0.24 | -0.22 | -0.33 | — |
| Weighted avg. shares (diluted) | 12.99M | 12.12M | 10.95M | — | 9.88M | 8.52M | 7.46M | — |
| Banking | ||||||||
| Deposits | — | $31,174 | $29,585 | $28,660 | $37,160 | $31,927 | $37,684 | $32,527 |
| Balance sheet | ||||||||
| Cash & equivalents | $4.48M | $8.32M | $7.08M | $4.97M | $4.38M | $5.99M | $2.01M | $3.70M |
| Receivables | $809,341 | $432,925 | $385,009 | $195,703 | $108,504 | $128,518 | $243,708 | $244,618 |
| Inventory | $254,656 | $277,308 | $238,282 | $257,132 | $110,256 | $131,432 | $37,421 | $44,328 |
| Current assets | $6.05M | $9.41M | $8.14M | $5.73M | $4.99M | $6.62M | $2.54M | $4.27M |
| PP&E, net | $56,921 | $65,463 | $67,530 | $75,564 | $85,473 | $101,104 | $103,715 | $89,982 |
| Intangibles | $263,734 | $258,214 | $266,494 | $274,778 | $283,062 | $91,345 | $93,967 | $96,588 |
| Total assets | $6.66M | $10.00M | $8.75M | $6.40M | $5.78M | $7.09M | $3.03M | $4.76M |
| Current liabilities | $2.89M | $3.10M | $2.81M | $2.79M | $3.15M | $2.35M | $2.10M | $2.43M |
| Short-term debt | $207,306 | $42,726 | $100,735 | $148,293 | $195,658 | $121,433 | $84,307 | $154,152 |
| Total liabilities | $3.03M | $3.26M | $3.00M | $3.00M | $3.49M | $2.83M | $2.77M | $2.69M |
| Shareholders' equity | $3.62M | $6.74M | $5.75M | $3.40M | $2.28M | $4.25M | $258,479 | $2.07M |
| Shares outstanding | 13.81M | 12.47M | 11.45M | 10.65M | 9.89M | 9.86M | 7.22M | 6.99M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.27M | -$1.03M | -$1.23M | -$1.93M | -$1.43M | -$1.47M | -$1.60M | -$1.76M |
| Capital expenditure | $0 | — | — | $5,862 | $0 | $7,288 | $18,000 | $0 |
| Free cash flow | -$2.27M | — | — | -$1.94M | -$1.43M | -$1.47M | -$1.62M | -$1.76M |
| Investing cash flow | -$13,800 | — | — | -$105,862 | $0 | -$7,288 | -$18,000 | $0 |
| Financing cash flow | -$1.56M | $2.28M | $3.34M | $2.63M | -$183,808 | $5.46M | -$69,845 | $5.19M |
| Depreciation & amortization | $16,821 | $16,650 | $16,317 | $24,055 | $16,205 | $12,885 | $6,356 | $6,851 |
| Stock-based compensation | $4.06M | $0 | $329,434 | $157,136 | $0 | $0 | $105,811 | $0 |
Free plan shows the latest 8 periods; Pro shows all 19 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.